Special Issue

Developmental Origins and Emerging Therapeutic Opportunities for Uterine Fibroids

Message from the Guest Editors

We are pleased to invite you to publish your research results in a new Special Issue concerning developmental origins and emerging therapeutic opportunities for uterine fibroids (UFs). It is currently known that uterine fibroids are the most common benign tumors occurring in women of reproductive age. Numerous treatment modalities are available ranging from completely non-invasive treatments with the use of drugs or various new devices, through minimally invasive procedures including myomectomies, and ending with hysterectomy. We see the area for new studies regarding known but not yet fully elucidated pathways as well as novel treatment options and approaches. It is vital that this Special Issue includes the presentation of new biological pathways involved in the development and growth of UFs and substances by which they are influenced. We also want to present new compounds which present anti-UF activity or combined therapies which aim at the reduction of invasiveness with a simultaneous increase in the effectiveness of UF treatment.

Guest Editors

Prof. Dr. Ayman Al-Hendy

Prof. Dr. Michał Ciebiera

Dr. Mohamed Ali

Deadline for manuscript submissions

closed (31 October 2021)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/60085

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceutica

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals*.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

